



Attorney Docket Number: 34150/0013

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Reinl et al.

Serial No.: 09/667,237

Art Unit: 1639

Filed: September 22, 2000

) Examiner: Mark L. SHIBUYA
)

) I hereby certify that this correspondence is being
) deposited with the United States Postal Service as
) first class mail in an envelope addressed to:
) Mail Stop Amendment, Commissioner for Patents,
) P.O. Box 1450, Alexandria, VA 22313-1450
) on August 22, 2006
)

) by _____
) Wayne P. Fitzmaurice
) Reg. No. 58,274

For: Creation of Variable Length & Sequence Linker Regions for
Dual-Domain or Multi-Domain Molecules

MS Amendment
U.S. Patent & Trademark Office
P.O. Box 1450
Alexandria, VA 22313-1450

**Statement that the Content of the Paper and Computer
Readable Copies are the Same Pursuant to 37 CFR 1.821(f)**

Sir:

Submitted herewith is the sequence listing in computer readable form in duplicate on compact disk. Also submitted is the sequence listing in paper form. I hereby state that the information recorded in computer readable form is identical to the written sequence listing. I hereby state that the sequence listing contain no new matter.

Date: August 22, 2006

Respectfully Submitted,

Wayne P. Fitzmaurice, Reg. No. 58,274
Senior Director
Large Scale Biology Corporation
3333 Vaca Valley Parkway, Suite 1000
Vacaville, CA 95688
Telephone: (707) 469-2395
Fax: (707) 446-3917

**UNITED STATES DEPARTMENT OF COMMERCE****U.S. Patent and Trademark Office**

Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450

APPLICATION NO./ CONTROL NO.	FILING DATE	FIRST NAMED INVENTOR / PATENT IN REEXAMINATION	ATTORNEY DOCKET NO.
---------------------------------	-------------	---	---------------------

09/667,237 9122/2000 REINL

3415/0013

EXAMINER

Shibuya

ART UNIT

PAPER

1639

20060616

DATE MAILED:

Please find below and/or attached an Office communication concerning this application or proceeding.

Commissioner for Patents


This application contains sequence disclosures that are encompassed by the definitions for nucleotide and/or amino acid sequences set forth in 37 CFR 1.821(a)(1) and (a)(2). However, this application fails to comply with the requirements of 37 CFR 1.821 through 1.825 for the reason(s) set forth below or on the attached Notice To Comply With Requirements For Patent Applications Containing Nucleotide Sequence And/Or Amino Acid Sequence Disclosures.

Particularly, claim 49 recites the sequence Gly4Ser, which is within the sequence rules, but Gly4Ser is not listed in the paper copy of the sequence listing and is not listed in the computer readable form. Furthermore, claim 49, does not identify by SEQ ID this amino acid sequence (Gly4Ser). Also, the instant specification, at p. 14, line 15, states this amino acid sequence, but does not identify this amino acid sequence by SEQ ID. Applicant must correct these deficiencies. Applicant's assistance is respectfully requested in identifying other instances, if any, wherein the specification or claims do not conform to the sequence rules.

Applicant is given ONE MONTH, or THIRTY DAYS, whichever is longer, from the mailing date of this letter within which to comply with the sequence rules, 37 CFR 1.821 - 1.825. Failure to comply with these requirements will result in ABANDONMENT of the application under 37 CFR 1.821(g). Extensions of time may be obtained by filing a petition accompanied by the extension fee under the provisions of 37 CFR 1.136(a). In no case may an applicant extend the period for reply beyond the SIX MONTH statutory period. Direct the reply to the undersigned. Applicant is requested to return a copy of the attached Notice to Comply with the reply.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Mark Shibuya, PhD, whose telephone number is (571) 272-0806. The examiner can normally be reached on Monday-Friday from 8:30am to 5:00pm. If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Andrew Wang, of Art Unit 1639, can be reached at (571) 272-0811. The fax phone number for the organization where this application or proceeding is assigned is (571) 273-8300. Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the receptionist whose telephone number is (571) 272-1600. Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).


MARK SHIBUYA, PH.D.
PATENT EXAMINER



Notice to Comply	Application No. 091667, 237	Applicant(s) REINL	
	Examiner Shibuya	Art Unit 1639	

NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES

Applicant must file the items indicated below within the time period set in the Office action to which the Notice is attached to avoid abandonment under 35 U.S.C. § 133 (extensions of time may be obtained under the provisions of 37 CFR 1.136(a)).

The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 C.F.R. 1.821 - 1.825 for the following reason(s):

- ☒ 1. This application clearly fails to comply with the requirements of 37 C.F.R. 1.821-1.825. Applicant's attention is directed to the final rulemaking notice published at 55 FR 18230 (May 1, 1990), and 1114 OG 29 (May 15, 1990). If the effective filing date is on or after July 1, 1998, see the final rulemaking notice published at 63 FR 29620 (June 1, 1998) and 1211 OG 82 (June 23, 1998).
- ☐ 2. This application does not contain, as a separate part of the disclosure on paper copy, a "Sequence Listing" as required by 37 C.F.R. 1.821(c).
- ☐ 3. A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 C.F.R. 1.821(e).
- ☐ 4. A copy of the "Sequence Listing" in computer readable form has been submitted. However, the content of the computer readable form does not comply with the requirements of 37 C.F.R. 1.822 and/or 1.823, as indicated on the attached copy of the marked -up "Raw Sequence Listing."
- ☐ 5. The computer readable form that has been filed with this application has been found to be damaged and/or unreadable as indicated on the attached CRF Diskette Problem Report. A Substitute computer readable form must be submitted as required by 37 C.F.R. 1.825(d).
- ☐ 6. The paper copy of the "Sequence Listing" is not the same as the computer readable form of the "Sequence Listing" as required by 37 C.F.R. 1.821(e).
- ☒ 7. Other: Please see attached sheets.

Applicant Must Provide:

- ☒ An initial or substitute computer readable form (CRF) copy of the "Sequence Listing".
- ☒ An initial or substitute paper copy of the "Sequence Listing", as well as an amendment directing its entry into the specification.
- ☒ A statement that the content of the paper and computer readable copies are the same and, where applicable, include no new matter, as required by 37 C.F.R. 1.821(e) or 1.821(f) or 1.821(g) or 1.825(b) or 1.825(d).

For questions regarding compliance to these requirements, please contact:

For Rules Interpretation, call (571) 272-2510

For CRF Submission Help, call (571) 272-2501/2583.

PatentIn Software Program Support

Technical Assistance.....703-287-0200

To Purchase PatentIn Software.....703-306-2600

PLEASE RETURN A COPY OF THIS NOTICE WITH YOUR REPLY